PAINWeek 2017 Keynote: Can Policy Possibly Protect Patients?
Terms such as "opioid McCarthyism" and "witch hunt" were used to express frustration with current opioid regulatory efforts.
Migraine Patients Need to Hear: It’s Physiologic and Treatable
From PAINWeek 2017: Reflex vasodilation is out, neurobiologic dysfunction is in as explanation for migraine etiology.
Opioid Prescribers Confront Multiple Regulatory Agencies
An early session at PAINWeek 2017 addressed prescriber fear as regulatory agencies "pile on" across overlapping jurisdictions.
Treatment Strategies to Limit Hypoglycemia
Studies summarized in this slide show focus on fine-tuning insulin-containing regimens to enhance glucose control and avoid variability.
ADA 2017: Hypoglycemia and the Role of Glycemic Variability
Glycemic variability fuels hypoglycemia but in one study from ADA 2017 is found to actually help predict hypoglycemic events.
ADA 2017: Evaluating Cardiovascular Safety of Antidiabetic Agents
Cardiovascular risk/benefit profiles of pioglitazone and the SGLT2 inhibitor class are summarized, based on reports at ADA 2017.
ADA 2017: CV Complications of Diabetes
A1C vs FPG to diagnose prediabetes; prediabetes and CHF; and how much weight loss is too much? Reports from ADA 2017.
ADA 2017: Oral Agents Under Review
When to start screening for B12 deficiency in your diabetes patients taking metformin? We review a dose-response diet study plus 2 others on oral drugs.
ADA 2017: Insulins go Head-to-Head
Insulin degludec vs glargine--which costs less per anum and why? We summarize this study and 2 other direct insulin comparisons reported at ADA 2017.
Prescribers Counseled on Defensible Pain Treatment Practice
"Ladies and gentlemen of the jury," began the PAINWeek 2016 speaker, in mock trial defense of a physician for over-prescribing opioid meds.